George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- June15 2004
- Volume 11
- Issue 11
Caller ID for Telemarketers
Author(s)Michael Sheehan
Advertisement
Note:
The best way to cut back on unwantedtelemarketing calls is to sign up forthe Federal Trade Commission's (FTC)national do-not-call registry. If you havenot done that already, contact the FTC(888-382-1222; www.donotcall.gov).Until then, you can screen telemarketersthrough your caller ID. FTC rules nowrequire that caller IDs display the name ofthe company making the call or trying tomake a sale. The information must alsoinclude a phone number that consumerscan use to ask to be removed from thecompany's call list. Until now, telemarketingcalls were displayed as "out of area"on caller IDs. In areas where callerID is not available, companies do have tocomply with the new regulations.
Articles in this issue
about 18 years ago
Georgia: Walk Down the Antebellum Trailabout 18 years ago
Tarrytown Welcomes Weekend Film Criticsabout 18 years ago
Land Rover Discovery 3:In Style and Off-Roadabout 18 years ago
Customize Your Own Investing Approachabout 18 years ago
Martha's Lesson: Be Careful with Tipsabout 18 years ago
School Your Children on the Stock Marketabout 18 years ago
Recite the ABCs of the Share Classesabout 18 years ago
Offset Volatility with Some Clever Varietyabout 18 years ago
Model Portfolio Series: Equity Incomeabout 18 years ago
Beat the Heat of the Rising Interest RatesAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5